Authorized purpose: TruSPECT Radiological Image Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals in the labeled SPECT workflow.
Clinical role
PET or nuclear-medicine acquisition, reconstruction, visualization, quantitative review, and release-specific processing support.
Images and patients
PET/SPECT/Nuclear Medicine · Heart and other organs represented in SPECT studies
Key limitation
Keep in mind: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: TruSPECT Radiological Image Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals in the labeled SPECT workflow.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Heart and other organs represented in SPECT studies Input: Positron-emission or radioisotope-tracer data, CT transmission data, patient information, and supported studies.
Who uses it?Intended users: Qualified nuclear-medicine physicians, radiologists, technologists, and other trained PET/CT professionals.
What does the software produce?Output: Processed PET, SPECT, CT, fused, quantitative, or planning images for professional interpretation.
What is its most important limitation?Key limitation: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
Clinical takeaway. Clinical role: TruSPECT Radiological Image Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals in the labeled SPECT workflow.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports design control testing and software verification and validation for a Moderate level of concern, and states TruSPECT did not require clinical studies. Performance testing of the AI-based algorithm for iteration reconstruction to control image attenuation used test datasets of representative clinical exams, with ground truth from experienced NM Physicists and Physicians, who also scored the results on a 5-point Likert scale; no dataset size or numeric results are given. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
TruSPECT Radiological Image Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals in the labeled SPECT workflow.
The exact FDA document reports design control testing and software verification and validation for a Moderate level of concern, and states TruSPECT did not require clinical studies. Performance testing of the AI-based algorithm for iteration reconstruction to control image attenuation used test datasets of representative clinical exams, with ground truth from experienced NM Physicists and Physicians, who also scored the results on a 5-point Likert scale; no dataset size or numeric results are given. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Proposed TruSPECT and its clinical applications successfully completed all design control testing" … "Software verification and validation for a Moderate level of concern, without unexpected results.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports design control testing and software verification and validation for a Moderate level of concern, and states TruSPECT did not require clinical studies. Performance testing of the AI-based algorithm for iteration reconstruction to control image attenuation used test datasets of representative clinical exams, with ground truth from experienced NM Physicists and Physicians, who also scored the results on a 5-point Likert scale; no dataset size or numeric results are given. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Proposed TruSPECT and its clinical applications successfully completed all design control testing" … "Software verification and validation for a Moderate level of concern, without unexpected results.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K212230 FDA evidence package for TruSPECT Radiological Image Processing Station
DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
PopulationHeart and other organs represented in SPECT studies
Scopeexact submission
Tested versionTruSPECT Radiological Image Processing Station configuration described in K212230
IndependenceSponsor or vendor study
K212230
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K212230 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Positron-emission or radioisotope-tracer data, CT transmission data, patient information, and supported studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes TruSPECT as intended for acceptance, transfer, display, storage, and processing of images, able to be integrated with the D-SPECT cardiac scanner system, with SUMO workflow results exportable to EP systems. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "TruSPECT is intended for acceptance, transfer, display, storage, and processing of images for detection of radioisotope tracer uptakes in the patient's body." … "The results generated by the SUMO workflow can be displayed on the D-SPECT processing station and additionally, can be exported to EP systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes TruSPECT as a Windows-based processing workstation that can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station, and as software loadable onto a customer workstation that meets specification. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "TruSPECT is based on Windows operating system." … "TruSPECT is a processing workstation primarily intended for, but not limited to cardiac applications. The workstation can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Processed PET, SPECT, CT, fused, quantitative, or planning images for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes TruSPECT as a Windows-based processing workstation that can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station, and as software loadable onto a customer workstation that meets specification. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "TruSPECT is based on Windows operating system." … "TruSPECT is a processing workstation primarily intended for, but not limited to cardiac applications. The workstation can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes TruSPECT as intended for acceptance, transfer, display, storage, and processing of images, able to be integrated with the D-SPECT cardiac scanner system, with SUMO workflow results exportable to EP systems. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "TruSPECT is intended for acceptance, transfer, display, storage, and processing of images for detection of radioisotope tracer uptakes in the patient's body." … "The results generated by the SUMO workflow can be displayed on the D-SPECT processing station and additionally, can be exported to EP systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Only qualified nuclear-medicine physicians, radiologists, technologists, and other trained pet/ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K212230 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K212230 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. PET/CT or nuclear-medicine imaging system or processing function limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: uMI Panvivo variants acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, attenuation correction, and the labeled body-region workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Authorized purpose: uMI Panvivo PET/CT acquires anatomical CT and functional PET images of radiopharmaceutical distribution for qualified diagnostic and treatment-planning workflows, including labeled lung-cancer-screening use.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head and neck, cardiac, and other labeled PET/CT regions
Authorized purpose: TruSPECT Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals; TruClear AI SPECT enhancement supports the existing image-processing workflow and does not replace clinical judgment.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Heart, organs, and body regions represented in SPECT studies
Authorized purpose: Cartesion Prime PET/CT acquires cross-sectional CT images and PET radiopharmaceutical-distribution images and includes AiCE-i PET processing and a neural-network respiratory-gating workflow for supported examinations.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head, neck, cardiac, and other labeled PET/CT regions
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.